{
  "symbol": "VYGR",
  "company_name": "Voyager Therapeut",
  "ir_website": "https://ir.voyagertherapeutics.com/",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease",
          "url": "https://ir.voyagertherapeutics.com/news-releases/news-release-details/voyager-selects-tau-silencing-gene-therapy-development-candidate",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ![Voyager Therapeutics Inc. Logo](/sites/g/files/knoqqb89791/themes/site/client_site_202/local/images/Voyager_logo_web.png) ](https://www.voyagertherapeutics.com/)\n\n  * [About](https://www.voyagertherapeutics.com/about-overview/)\n  * [Pipeline](https://www.voyagertherapeutics.com/pipeline-overview/)\n  * [Science](https://www.voyagertherapeutics.com/science-overview/)\n  * [Investors](/)\n  * [Careers](https://www.voyagertherapeutics.com/careers-overview/)\n\n\n\n![](/sites/g/files/knoqqb89791/themes/site/client_site_202/local/images/hamburger-icon.png)\n\n![Voyager hamburger close](/sites/g/files/knoqqb89791/themes/site/client_site_202/local/images/Voyager_hamburger_close.png)\n\n[ ![Voyager Therapeutics Inc. Logo](/sites/g/files/knoqqb89791/themes/site/client_site_202/local/images/Voyager_logo_web.png) ](https://www.voyagertherapeutics.com/)\n\nAbout\n\n[Overview](https://www.voyagertherapeutics.com/about-overview/)\n\n[Vision, Mission, & Strategy](https://www.voyagertherapeutics.com/about-vision-mission-strategy/)\n\n[Management Team](https://www.voyagertherapeutics.com/about-leadership/)\n\n[Board of Directors](https://www.voyagertherapeutics.com/about-leadership/#bod)\n\n[Scientific Advisory Board](https://www.voyagertherapeutics.com/about-leadership/#sab)\n\n[Core Values](https://www.voyagertherapeutics.com/about-core-values/)\n\nPipeline\n\n[Overview](https://www.voyagertherapeutics.com/pipeline-overview/)\n\n[• VY7523 for Alzheimer’s](https://www.voyagertherapeutics.com/pipeline-overview/?popup=vy7523)\n\n[• Alzheimer’s early research](https://www.voyagertherapeutics.com/pipeline-overview/?popup=alzheimers)\n\n[• SOD1 for ALS](https://www.voyagertherapeutics.com/pipeline-overview/?popup=sod1)\n\n[Patient Resources](https://www.voyagertherapeutics.com/patient-resources/)\n\n[Partnerships](https://www.voyagertherapeutics.com/science-partnerships/)\n\nScience\n\n[Overview](https://www.voyagertherapeutics.com/science-overview/)\n\n[TRACER Platform](https://www.voyagertherapeutics.com/science-tracer/)\n\n[Non-Viral Delivery](https://www.voyagertherapeutics.com/science-non-viral/)\n\n[Publications & Presentations](https://www.voyagertherapeutics.com/science-publications/)\n\n[Partnerships](https://www.voyagertherapeutics.com/science-partnerships/)\n\nInvestors\n\n[Overview](/)\n\n[Press Releases](/press-releases)\n\n[Events & Presentations](/events-presentations)\n\n[Financials](/financial-information/sec-filings)\n\n[Stock Information](/stock-information/stock-quote)\n\n[Shareholder Services](/shareholder-services/investor-faqs)\n\nCareers\n\n[Overview](https://www.voyagertherapeutics.com/careers-overview/)\n\n[Job Openings](https://boards.greenhouse.io/voyagertherapeutics/)\n\n[Our Community](https://www.voyagertherapeutics.com/careers-culture/)\n\n[Mission & Values](https://www.voyagertherapeutics.com/about-core-values/)\n\n[Benefits](https://www.voyagertherapeutics.com/careers-benefits/)\n\n[Disclosures](https://www.voyagertherapeutics.com/careers-disclosures/)\n\nAbout\n\n[Overview](https://www.voyagertherapeutics.com/about-overview/)\n\n[Vision, Mission, & Strategy](https://www.voyagertherapeutics.com/about-vision-mission-strategy/)\n\n[Management Team](https://www.voyagertherapeutics.com/about-leadership/)\n\n[Board of Directors](https://www.voyagertherapeutics.com/about-leadership/#bod)\n\n[Scientific Advisory Board](https://www.voyagertherapeutics.com/about-leadership/#sab)\n\n[Core Values](https://www.voyagertherapeutics.com/about-core-values/)\n\nPipeline\n\n[Overview](https://www.voyagertherapeutics.com/pipeline-overview/)\n\n[• VY7523 for Alzheimer’s](https://www.voyagertherapeutics.com/pipeline-overview/?popup=vy7523)\n\n[• Alzheimer’s early research](https://www.voyagertherapeutics.com/pipeline-overview/?popup=alzheimers)\n\n[• SOD1 for ALS](https://www.voyagertherapeutics.com/pipeline-overview/?popup=sod1)\n\n[Patient Resources](https://www.voyagertherapeutics.com/patient-resources/)\n\n[Partnerships](https://www.voyagertherapeutics.com/science-partnerships/)\n\nScience\n\n[Overview](https://www.voyagertherapeutics.com/science-overview/)\n\n[TRACER Platform](https://www.voyagertherapeutics.com/science-tracer/)\n\n[Non-Viral Delivery](https://www.voyagertherapeutics.com/science-non-viral/)\n\n[Publications & Presentations](https://www.voyagertherapeutics.com/science-publications/)\n\n[Partnerships](https://www.voyagertherapeutics.com/science-partnerships/)\n\nInvestors\n\n[Overview](/)\n\n[Press Releases](/press-releases)\n\n[Events & Presentations](/events-presentations)\n\n[Financials](/financial-information/sec-filings)\n\n[Stock Information](/stock-information/stock-quote)\n\n[Shareholder Services](/shareholder-services/investor-faqs)\n\nCareers\n\n[Overview](https://www.voyagertherapeutics.com/careers-overview/)\n\n[Job Openings](https://boards.greenhouse.io/voyagertherapeutics/)\n\n[Our Community](https://www.voyagertherapeutics.com/careers-culture/)\n\n[Mission & Values](https://www.voyagertherapeutics.com/about-core-values/)\n\n[Benefits](https://www.voyagertherapeutics.com/careers-benefits/)\n\n[Disclosures](https://www.voyagertherapeutics.com/careers-disclosures/)\n\nSearch for:\n\n# Release Details\n\n  * [Overview](/ \"Main Investor Relations Page\")\n  * [Press Releases](/press-releases)\n  * [Events & Presentations](/events-presentations)\n  * [Financials](/financial-information/sec-filings)\n    * [SEC Filings](/financial-information/sec-filings)\n    * [Annual Reports](/financial-information/annual-reports)\n  * [Stock Information](/stock-information/stock-quote)\n    * [Stock Quote & Chart](/stock-information/stock-quote)\n  * [Corporate Governance]()\n    * [Leadership Team](https://www.voyagertherapeutics.com/about-leadership/#managementteam)\n    * [Board of Directors](https://www.voyagertherapeutics.com/about-leadership/#bod)\n    * [Scientific Advisors](https://www.voyagertherapeutics.com/about-leadership/#sab \"Code of Conduct\")\n    * [Committee Composition](/corporate-governance/committee-composition)\n    * [Documents & Charters](/corporate-governance/highlights)\n    * [Contact the Board](/corporate-governance/contact-the-board)\n  * [Shareholder Services](/shareholder-services/investor-faqs)\n    * [Investor FAQs](/shareholder-services/investor-faqs)\n    * [Analyst Coverage](/shareholder-services/analyst-coverage)\n    * [Contact Us](/shareholder-services/document-request)\n    * [Email Alerts](/shareholder-services/email-alerts)\n\n\n\n## \n\nVoyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease\n\n11/20/24\n\n[PDF Version](/node/12201/pdf)\n\n_- Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in 2026 -_\n\n_- VY1706 is the fifth neuro gene therapy development candidate nominated leveraging Voyager’s_ _IV-delivered, CNS-penetrant TRACER capsids -_\n\nLEXINGTON, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it has selected a lead development candidate, VY1706, for its tau silencing gene therapy program in Alzheimer’s disease. The Company anticipates filing an investigational new drug (IND) application with the U.S. Food and Drug Administration and a clinical trial application (CTA) with Health Canada for VY1706 in 2026.\n\nVY1706 combines a potent siRNA construct to decrease the expression of tau with an IV-delivered, blood-brain barrier-penetrant TRACER™ capsid. In a non-human primate (NHP) study, a single dose of VY1706 resulted in reductions in tau mRNA levels of 50% to 73% across the cerebral cortex, including in areas of the brain where tau accumulates during progression of Alzheimer’s disease. Voyager expects to present these and additional data at an upcoming scientific conference.\n\n“The nomination of this tau silencing development candidate VY1706, along with the ongoing clinical trial of our anti-tau antibody VY7523, demonstrate our conviction that tau is an important target in Alzheimer’s disease,” said Toby Ferguson, M.D., Ph.D., Chief Medical Officer of Voyager. “We have seen third-party data indicating that both a tau antibody and a tau knockdown approach can impact tau accumulation in a human brain, and that this may correlate with clinical benefit. We will continue to assess and learn from emerging data in this field as we efficiently progress our differentiated tau antibody and tau gene therapy programs towards human proof-of-concept.”\n\n**About Alzheimer’s Disease** Alzheimer’s disease is a progressive neurodegenerative disease estimated to affect 7 million people in the U.Si and up to 416 million people globallyii. The disease causes memory loss and may escalate to decreased independence, communication challenges, behavioral disorders such as paranoia and anxiety, and lack of physical controliii. In 2023, the total cost of caring for people living with Alzheimer’s and other dementias in the U.S. was estimated at $345 billioniv.\n\n**About the TRACER™ Capsid Discovery Platform** Voyager’s TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) capsid discovery platform is a broadly applicable, RNA-based screening platform that enables rapid discovery of novel AAV capsids to enable gene therapy. Voyager has leveraged TRACER to create multiple families of novel capsids that, following intravenous delivery in preclinical studies, harness the extensive vasculature of the central nervous system (CNS) to cross the blood-brain barrier and transduce a broad range of CNS regions and cell types. In cross-species preclinical studies (rodents and multiple non-human primate species), intravenous delivery of TRACER-generated capsids resulted in widespread payload expression across the CNS at relatively low doses, enabling selection of multiple development candidates in Voyager’s wholly-owned and partnered gene therapy programs for neurologic diseases.\n\n**About Voyager Therapeutics**Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more information, visit [www.voyagertherapeutics.com](https://www.globenewswire.com/Tracker?data=6KlSYgBZnumMm2flCWk-Cf8k-UXcSks6MULDYFsnaHw963sQI9ix2BUPSLZeKaj3Y81yZIULZLtnwZqGc71xvEJmNLBTQY1-g6Ll2gML9eRGVmbcGumpKtJP0MluX1k1).\n\n_Voyager Therapeutics ® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc. _\n\n**Forward-Looking Statements**\n\nThis press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “expect,” “anticipate,” “potential,” “may,” or “continue,” and other similar expressions are intended to identify forward-looking statements.\n\nFor example, all statements Voyager makes regarding Voyager’s ability to advance its AAV-based gene therapy programs and tau antibody program, including expectations for Voyager’s achievement of preclinical and clinical development milestones for its potential development candidates, such as the identification of lead development candidates, IND and CTA filings, the initiation of clinical trials, clinical trial enrollment, and the generation of clinical data and proof-of-concept; Voyager’s expectations for the presentation of additional data from its tau silencing gene therapy development candidate at a future scientific conference; the potential for an antibody or gene therapy targeting tau to impact tau accumulation in a human brain and for this impact to correlate to clinical benefit; and the potential for third-party clinical data to inform Voyager’s clinical development plans are forward looking.\n\nAll forward-looking statements are based on estimates and assumptions by Voyager’s management that, although Voyager believes such forward-looking statements to be reasonable, are inherently uncertain and subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected. Such risks and uncertainties include, among others, the expectations and decisions of regulatory authorities; the timing, initiation, conduct and outcomes of Voyager’s preclinical and clinical studies; the availability of data from clinical trials; the availability or commercial potential of product candidates under collaborations; the success of Voyager’s product candidates; the willingness and ability of Voyager's collaboration partners to meet obligations under collaboration agreements with Voyager; the continued development of Voyager’s technology platforms, including Voyager’s TRACER platform and its antibody screening technology; Voyager’s scientific approach and program development progress, and the restricted supply of critical research components; the development by third parties of capsid identification platforms that may be competitive to Voyager’s TRACER capsid discovery platform; Voyager’s ability to create and protect intellectual property rights associated with the TRACER capsid discovery platform, the capsids identified by the platform, and development candidates for Voyager’s pipeline programs; the possibility or the timing of Voyager’s receipt of program reimbursement, development or commercialization milestones, option exercise, and other payments under Voyager’s existing licensing or collaboration agreements; the ability of Voyager to negotiate and complete licensing or collaboration agreements with other parties on terms acceptable to Voyager and the third parties; the success of programs controlled by third-party collaboration partners in which Voyager retains a financial interest; the ability to attract and retain talented directors, employees, and contractors; and the sufficiency of Voyager’s cash resources to fund its operations and pursue its corporate objectives.\n\nThese statements are also subject to a number of material risks and uncertainties that are described in Voyager’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission. All information in the press release is as of the date of this press release, and any forward-looking statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise this information or any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.\n\n**Contacts** Trista Morrison, NACD.DC, [tmorrison@vygr.com](https://www.globenewswire.com/Tracker?data=2BTuc1oNnvVd8R1Kvd6KC2nZynooQv9lxjaBiHd2Xw1tl5TzjPfnqW3z1ietWdNkGbRYMWFPVlQ9R4-PUn60gj9K1s1hulUrMSfrCUeth-A=)Investors: Michael Hencke, [mhencke@kendallir.com](https://www.globenewswire.com/Tracker?data=TIZ-7NYsITK8vkbsJ0YoxIED-VGklIQ3WzFlzfH4VvvWCgcvUKb0Apj5w0E4ordeGMIKHda7GZlkwdsUuew7eflBBirD3m91BIkUJBvJJXU=)Media: Brooke Shenkin, [brooke@scientpr.com](https://www.globenewswire.com/Tracker?data=HPwKk5o67Q-NuF7W7HXaDX31wTg-0EHzWabfhHrKu1TMW4_fYWOJ7XGRfi8PH580Fwe3fjZ5lvRCTrw-IL-_LegFuMmaNLWN2fDRQUW1NAE=)\n\nReferences:\n\ni. Alzheimer’s Association. 2023 Alzheimer’s Facts and Figures. Available at: [https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf](https://www.globenewswire.com/Tracker?data=Xsr7m62rR50aJJNoFMxnVVLptaWz4EEJ6YhU-_yTasPGNqSduZD5vSkuK6gSzkJuA45476HMFJdbceJn5cRQxtMGohASf1cUvlg3yhPWqWU9N6c-RWJQd2HjOm4kSNMdVDPlMG8jxjODFVwrlf871uFzvcikqw3l7tJe95iuFtOSe5uvSznrrzlMQRIA0PFZW8JG5tc_4GxYx-f6xmVpt5N3kf4Nd1roTe6LgEpgPBI=). Accessed November 12, 2024.ii. Gustavsson A, Norton N, Fast T, et al. Global estimates on the number of persons across the Alzheimer’s disease continuum.  _Alzheimer’s Dement_. 2023; 19: 658–670. doi: 10.1002/alz.12694.iii. Penn Medicine. The 7 Stages of Alzheimer’s Disease. Available at: [https://www.pennmedicine.org/updates/blogs/neuroscience-blog/2019/november/stages-of-alzheimers](https://www.globenewswire.com/Tracker?data=Xsr7m62rR50aJJNoFMxnVY3sIcQC_iMKLVOVMOcWcp4Q27uQFp-QtQi1yC7bjGD8PLw11LhofxnEZiN5wku3wM98EudAcgkCmPXaHqMRireieIC3t415yam7pEkqxFatIGOTj4Xz37CFYm2JxqEMpsPpyk7KgwY1FEiXc-giEuV24r2IaYL2jjbzv-2RPdOclr0cLRh1kx48q3EURKKr5l8zTA5sl1w0SEqLdzYHXwlHFFpC0iEI3W7AsPu5MRh4d-5xbZKpACh-fnlr4kHtziqr_oRN6guBURECvH5VdiE=). Accessed November 12, 2024.iv. USAgainstAlzheimer’s. The Alzheimer’s Disease Crisis – By the Numbers. Available at: [The Alzheimer’s Disease Crisis – By the Numbers | ](https://www.globenewswire.com/Tracker?data=84bFE5rNReXOwQUKJSlsn-ZA4S4qYJS3fa3cRlJnXSXLqmOfuRMmZJXvNdYCHRJrc1F__KdUKUtc9wRN1AXJFe-3Nto5AUB9Ic3EKzWw8TG2tnT7iviP_Kn195lFyaFToSrPjvYYeppXI2--yzRZX1y8i3NJl6hDcjAkLjKUlS5giKwIz0ciJUWfvmheI1jj0aAVu9jHnlu3OUlabEDwstjjnpLNrP7LblfZuPYerQ0t2um0pcy6DEVzLW2kPxHfG4glMQmSRwJ_1EFgTVX4kVlk9BzAOezj2C2xAsQoVDC4-c5QOKxB5rPsUbJU9bVAGFetTLxplBwj54uWx-8EM1tX_4aJsd3-KEyqFwb30J2beDPoBDgvqSB9521IxS8rjyBqQwtRrt-qvjOWeFNwOCHOLV0tqJpt3Zg5CWdenvHGJPIrivxnYO5YTrSJne0xzJjYKa_fe8PFtIJAWY32jKpHGhXuK_g8jA6-VU73RHqTZcMUp2IbyKIzAiX2eS5w)[UsAgainstAlzheimer’s](https://www.globenewswire.com/Tracker?data=s6EBwqlU9nKIzfalI_HKM0XfOXQZhI8G1H_FAP57voRffln8FeBgWmMT8jDC3n6jsJeBweP2MQ_-_97wTJL_-LqBPJV5zNcsONhCfj2oQY0LZp1bipPRbGpqOoUsLawyyffOAVv5AkF5OsjEAbEH3q-RCf8V7oUcvgBNsLa2KArFlvWgQOyKKLnegIFEDMpMiYHzzy7LR60wcGakLFaHRg4k6eoVj1fYydaGQkfdkZzu4MxnepoZzZMa0EwDO4EuL9MJ3T67evBeSSi4Kp95HpHMtq44yz_6yDuYoBtkkCN3aWjLP2dZEQOmG1OJudmhvZOuJef0DoN1t2qMh_UuRpUjL3wJ_CIywMdl-HGmrr6EZjP8zerit8ZK5NBoGwVwFwRc2fIVCMc27BZ9WPwb73wY4rQL7O9kL1eZwnquHtt-UlYYteNDFawbz_HEvdkKT-nK8tCuK1S-62JymSWDNQ==)[ (](https://www.globenewswire.com/Tracker?data=PlOlHRfM0o1_9K76LrH4PXaS3jGpjBue1waCiawnbhk1hJTaZp8PhoEcVYOyd0dLXo9NjTkAccr-ctXPJ7clG55yITib7ODijiX7xbKWUarVcjLHsEX5BOl6RLTA5EGekrEJV61y_doPoBASKAsjrVhT3k3AWdd0brs8jcTer7ywUYuMvLDwO0cpVjcSNLNwO9xnY2DNuK4cdpwXruNtGIhY2uaYNHBsE8SU24QfC6824ZgRp6rZNA1vGZpIRIEZeR3iWkai0Pgp8iW_6xY17hNTqZx6PXUEsv5W9Zn5hJpKaMW5RZixt77LPqP6kKx7CGpvUCoO2QJeb5kuO-w9fFfM3Fb0kaF4hUp8EAWm4ovqjrZA-zCql9yvPxPSCzWVykBbEdJiHbF-s3pLfmuf6fg2kZCA87m_lNMZlzUAJd_8HznyVMXLFMp7OI6Jr5zv)[usagainstalzheimers.org](https://www.globenewswire.com/Tracker?data=abRjNUPWpfIrc17UvwRe2NwkAnk_gMmXIoSxZBdRCOYwOPlVhbO7s5H9ZfX1zAdMXyhAA8IWQtA1fYPyKvDSqs2EX89hp_P_buF5u0a0KA0=)). Accessed: November 12, 2024.\n\n![](https://www.globenewswire.com/newsroom/ti?nf=OTI3Njg0NyM2NTkxODMzIzIwMTg4NDA=)![](https://ml.globenewswire.com/media/MThjMjMwY2EtNDZlYS00YjVmLTg4ZmQtMWM1YjBjOTk5ZTY2LTEwMzA0MTM=/tiny/Voyager-Therapeutics-Inc-.png)\n\n[![Primary Logo](https://ml.globenewswire.com/media/f775f55a-83dd-4b38-bf92-bb9b588522bd/small/voyager-logos-square-logo-light-png.png)](https://www.globenewswire.com/NewsRoom/AttachmentNg/f775f55a-83dd-4b38-bf92-bb9b588522bd)\n\nSource: Voyager Therapeutics, Inc.\n"
        },
        {
          "title": "Voyager Reports Third Quarter 2024 Financial and Operating Results",
          "url": "https://ir.voyagertherapeutics.com/news-releases/news-release-details/voyager-reports-third-quarter-2024-financial-and-operating",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ![Voyager Therapeutics Inc. Logo](/sites/g/files/knoqqb89791/themes/site/client_site_202/local/images/Voyager_logo_web.png) ](https://www.voyagertherapeutics.com/)\n\n  * [About](https://www.voyagertherapeutics.com/about-overview/)\n  * [Pipeline](https://www.voyagertherapeutics.com/pipeline-overview/)\n  * [Science](https://www.voyagertherapeutics.com/science-overview/)\n  * [Investors](/)\n  * [Careers](https://www.voyagertherapeutics.com/careers-overview/)\n\n\n\n![](/sites/g/files/knoqqb89791/themes/site/client_site_202/local/images/hamburger-icon.png)\n\n![Voyager hamburger close](/sites/g/files/knoqqb89791/themes/site/client_site_202/local/images/Voyager_hamburger_close.png)\n\n[ ![Voyager Therapeutics Inc. Logo](/sites/g/files/knoqqb89791/themes/site/client_site_202/local/images/Voyager_logo_web.png) ](https://www.voyagertherapeutics.com/)\n\nAbout\n\n[Overview](https://www.voyagertherapeutics.com/about-overview/)\n\n[Vision, Mission, & Strategy](https://www.voyagertherapeutics.com/about-vision-mission-strategy/)\n\n[Management Team](https://www.voyagertherapeutics.com/about-leadership/)\n\n[Board of Directors](https://www.voyagertherapeutics.com/about-leadership/#bod)\n\n[Scientific Advisory Board](https://www.voyagertherapeutics.com/about-leadership/#sab)\n\n[Core Values](https://www.voyagertherapeutics.com/about-core-values/)\n\nPipeline\n\n[Overview](https://www.voyagertherapeutics.com/pipeline-overview/)\n\n[• VY7523 for Alzheimer’s](https://www.voyagertherapeutics.com/pipeline-overview/?popup=vy7523)\n\n[• Alzheimer’s early research](https://www.voyagertherapeutics.com/pipeline-overview/?popup=alzheimers)\n\n[• SOD1 for ALS](https://www.voyagertherapeutics.com/pipeline-overview/?popup=sod1)\n\n[Patient Resources](https://www.voyagertherapeutics.com/patient-resources/)\n\n[Partnerships](https://www.voyagertherapeutics.com/science-partnerships/)\n\nScience\n\n[Overview](https://www.voyagertherapeutics.com/science-overview/)\n\n[TRACER Platform](https://www.voyagertherapeutics.com/science-tracer/)\n\n[Non-Viral Delivery](https://www.voyagertherapeutics.com/science-non-viral/)\n\n[Publications & Presentations](https://www.voyagertherapeutics.com/science-publications/)\n\n[Partnerships](https://www.voyagertherapeutics.com/science-partnerships/)\n\nInvestors\n\n[Overview](/)\n\n[Press Releases](/press-releases)\n\n[Events & Presentations](/events-presentations)\n\n[Financials](/financial-information/sec-filings)\n\n[Stock Information](/stock-information/stock-quote)\n\n[Shareholder Services](/shareholder-services/investor-faqs)\n\nCareers\n\n[Overview](https://www.voyagertherapeutics.com/careers-overview/)\n\n[Job Openings](https://boards.greenhouse.io/voyagertherapeutics/)\n\n[Our Community](https://www.voyagertherapeutics.com/careers-culture/)\n\n[Mission & Values](https://www.voyagertherapeutics.com/about-core-values/)\n\n[Benefits](https://www.voyagertherapeutics.com/careers-benefits/)\n\n[Disclosures](https://www.voyagertherapeutics.com/careers-disclosures/)\n\nAbout\n\n[Overview](https://www.voyagertherapeutics.com/about-overview/)\n\n[Vision, Mission, & Strategy](https://www.voyagertherapeutics.com/about-vision-mission-strategy/)\n\n[Management Team](https://www.voyagertherapeutics.com/about-leadership/)\n\n[Board of Directors](https://www.voyagertherapeutics.com/about-leadership/#bod)\n\n[Scientific Advisory Board](https://www.voyagertherapeutics.com/about-leadership/#sab)\n\n[Core Values](https://www.voyagertherapeutics.com/about-core-values/)\n\nPipeline\n\n[Overview](https://www.voyagertherapeutics.com/pipeline-overview/)\n\n[• VY7523 for Alzheimer’s](https://www.voyagertherapeutics.com/pipeline-overview/?popup=vy7523)\n\n[• Alzheimer’s early research](https://www.voyagertherapeutics.com/pipeline-overview/?popup=alzheimers)\n\n[• SOD1 for ALS](https://www.voyagertherapeutics.com/pipeline-overview/?popup=sod1)\n\n[Patient Resources](https://www.voyagertherapeutics.com/patient-resources/)\n\n[Partnerships](https://www.voyagertherapeutics.com/science-partnerships/)\n\nScience\n\n[Overview](https://www.voyagertherapeutics.com/science-overview/)\n\n[TRACER Platform](https://www.voyagertherapeutics.com/science-tracer/)\n\n[Non-Viral Delivery](https://www.voyagertherapeutics.com/science-non-viral/)\n\n[Publications & Presentations](https://www.voyagertherapeutics.com/science-publications/)\n\n[Partnerships](https://www.voyagertherapeutics.com/science-partnerships/)\n\nInvestors\n\n[Overview](/)\n\n[Press Releases](/press-releases)\n\n[Events & Presentations](/events-presentations)\n\n[Financials](/financial-information/sec-filings)\n\n[Stock Information](/stock-information/stock-quote)\n\n[Shareholder Services](/shareholder-services/investor-faqs)\n\nCareers\n\n[Overview](https://www.voyagertherapeutics.com/careers-overview/)\n\n[Job Openings](https://boards.greenhouse.io/voyagertherapeutics/)\n\n[Our Community](https://www.voyagertherapeutics.com/careers-culture/)\n\n[Mission & Values](https://www.voyagertherapeutics.com/about-core-values/)\n\n[Benefits](https://www.voyagertherapeutics.com/careers-benefits/)\n\n[Disclosures](https://www.voyagertherapeutics.com/careers-disclosures/)\n\nSearch for:\n\n# Release Details\n\n  * [Overview](/ \"Main Investor Relations Page\")\n  * [Press Releases](/press-releases)\n  * [Events & Presentations](/events-presentations)\n  * [Financials](/financial-information/sec-filings)\n    * [SEC Filings](/financial-information/sec-filings)\n    * [Annual Reports](/financial-information/annual-reports)\n  * [Stock Information](/stock-information/stock-quote)\n    * [Stock Quote & Chart](/stock-information/stock-quote)\n  * [Corporate Governance]()\n    * [Leadership Team](https://www.voyagertherapeutics.com/about-leadership/#managementteam)\n    * [Board of Directors](https://www.voyagertherapeutics.com/about-leadership/#bod)\n    * [Scientific Advisors](https://www.voyagertherapeutics.com/about-leadership/#sab \"Code of Conduct\")\n    * [Committee Composition](/corporate-governance/committee-composition)\n    * [Documents & Charters](/corporate-governance/highlights)\n    * [Contact the Board](/corporate-governance/contact-the-board)\n  * [Shareholder Services](/shareholder-services/investor-faqs)\n    * [Investor FAQs](/shareholder-services/investor-faqs)\n    * [Analyst Coverage](/shareholder-services/analyst-coverage)\n    * [Contact Us](/shareholder-services/document-request)\n    * [Email Alerts](/shareholder-services/email-alerts)\n\n\n\n## \n\nVoyager Reports Third Quarter 2024 Financial and Operating Results\n\n11/12/24\n\n[PDF Version](/node/12171/pdf)\n\n_- Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer’s; on track to generate top-line data H1 2025 -_\n\n_- Recent third-party clinical data establish that an antibody can inhibit tau accumulation in the human brain; provide support for use of an antibody to target tau in Alzheimer’s -_\n\n_- Continued partnership progress in Q3 2024 evidenced by new capsid license and new gene therapy development candidate selection -_\n\n_- INDs on track for three CNS gene therapies in 2025 in SOD1 ALS, GBA1 Parkinson’s and other GBA1-mediated disease, and Friedreich’s ataxia programs -_\n\nLEXINGTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today reported third quarter 2024 financial and operating results.\n\n“An increasing body of clinical evidence implicates tau as a critical target in Alzheimer’s disease,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. “Recent third-party clinical data give us increasing confidence that an antibody targeting the appropriate epitope of tau can slow the accumulation of tau in the brain of Alzheimer’s patients, and that this slowing may offer a clinically significant benefit in some patients. These encouraging data build on previous positive third-party clinical data with a tau silencing program and, we believe, support Voyager’s prioritization of both an anti-tau antibody and a tau silencing gene therapy. Our clinical-stage anti-tau antibody VY7523 is expected to generate initial tau PET imaging data in patients in H2 2026, and our tau silencing gene therapy is advancing toward IND in 2026. Our strong cash position of $345 million is expected to provide runway into 2027, enabling multiple data readouts.”\n\n**Third Quarter 2024 and Recent Highlights**\n\n  * **Licensed TRACER™ capsid to Novartis in 5****th****partnered program:** Voyager agreed to license to Novartis AG a novel TRACER capsid for use in a gene therapy program against an undisclosed rare neurologic disease target. This is the fifth partnered program between the two companies. Voyager received an upfront payment of $15 million in October and is eligible for up to $305 million in milestone payments, as well as royalties.\n  * **Achieved 3****rd****development candidate in partnership with Neurocrine:** The joint steering committee with collaborator Neurocrine Biosciences, Inc. selected a development candidate in a gene therapy program for the potential treatment of an undisclosed neurological disease, triggering a $3 million milestone payment to Voyager, which was received in October. This follows recent development candidate selections in programs for GBA1-mediated disorders and Friedreich’s ataxia.\n  * **VY7523 anti-tau antibody for Alzheimer’s disease:** Enrollment and dosing completed in the single ascending dose (SAD) clinical trial, with top-line safety and pharmacokinetic data expected in H1 2025.\n  * **Presented head-to-head preclinical data for murine surrogate of VY7523 vs. murine surrogates of other anti-tau antibodies:** Murine surrogate of VY7523 (C-terminal directed) demonstrated significant reduction in spread of human pathological tau in p301S mouse seeding model, as did murine surrogate of bepranemab (mid-domain directed). No significant reduction was seen for murine surrogates of two N-terminal directed antibodies that previously failed their primary endpoints in clinical trials. These data are expected to be presented at a future conference.\n\n\n\n**Anticipated Upcoming Milestones**\n\n  * H1 2025: Initial safety and pharmacokinetic data expected from VY7523 SAD clinical trial\n  * Mid-2025: U.S. IND and Canadian clinical trial application (CTA) filings expected with SOD1 silencing gene therapy VY9323 in ALS patients, subsequent clinical trial has potential to generate proof-of-concept based on biomarkers\n  * 2025: Initiation of Multiple Ascending Dose (MAD) clinical trial in AD patients expected with VY7523\n  * 2025: IND filings anticipated with NBIX-partnered GBA-1 and Friedreich’s ataxia gene therapies\n  * 2026: U.S. IND and Canadian CTA filings anticipated with tau silencing gene therapy for Alzheimer’s disease\n  * H2 2026: Initial tau PET imaging data expected in MAD clinical trial of VY7523 in Alzheimer’s disease\n\n\n\n**Third Quarter 2024 Financial Results**\n\n  * **Collaboration Revenues:** Voyager had collaboration revenue of $24.6 million for the third quarter of 2024, compared to $4.6 million for the same period in 2023. The increase was primarily due to increased revenue recognized under our Novartis and Neurocrine agreements.\n  * **Net Loss:** Net loss was $9.0 million for the third quarter of 2024, compared to net loss of $25.9 million for the same period in 2023. The decrease is primarily due to increased collaboration revenue recognized during the third quarter of 2024, as discussed above.\n  * **R &D Expenses:** Research and development expenses were $30.2 million for the third quarter of 2024, compared to $25.9 million for the same period in 2023. The increase in R&D expenses was primarily a result of increased targeted development team hires to support our advancing pipeline, along with increased facilities costs related to our lease for additional laboratory and office space.\n  * **G &A Expenses:** General and administrative expenses were $8.2 million for the third quarter of 2024, compared to $8.3 million for the same period in 2023. The consistent spend reflects continued disciplined expense management.\n  * **Cash Position:** Cash, cash equivalents and marketable securities as of September 30, 2024, were $345.4 million. This does not include the $15.0 million upfront payment from Novartis or the $3.0 million milestone payment from Neurocrine, both of which were received in October 2024.\n\n\n\n**Financial Guidance**\n\nVoyager is committed to maintaining a strong balance sheet that supports the advancement and growth of its platform and pipeline. Voyager continues to assess its planned cash needs both during the current period and in future periods. We expect our cash, cash equivalents, and marketable securities, along with amounts expected to be received as reimbursement for development costs under the Neurocrine and Novartis collaborations and interest income, to be sufficient to meet Voyager’s planned operating expenses and capital expenditure requirements into 2027.\n\n**Conference Call**\n\nVoyager will host a conference call and webcast today at 4:30 p.m. ET to discuss third quarter 2024 financial and operating results. A live webcast of the call will be available on the Investors section of the Voyager website at [https://ir.voyagertherapeutics.com/](https://www.globenewswire.com/Tracker?data=ry6WgJDYfbJQWj6q0Sb1vbR0jBsHOlU7r7ug4J1y1TBr8j3AlxNhZT79jC1axCNJDcaiYBSPZGLuFmTklqXtdYDzYd4zYZPq84VL6Cmj3IKfZP9ApuQiQee0jYkauCaC), and a replay of the call will be available at the same link approximately two hours after its completion. The replay will be available for at least 30 days following the conclusion of the call.\n\n**About Voyager Therapeutics**\n\nVoyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more information, visit [www.voyagertherapeutics.com](http://www.voyagertherapeutics.com).\n\n_Voyager Therapeutics ® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc. _\n\n**Forward-Looking Statements**\n\nThis press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “expect,” “believe,” “anticipate,” “potential,” or “continue,” and other similar expressions are intended to identify forward-looking statements.\n\nFor example, all statements Voyager makes regarding Voyager’s ability to advance its AAV-based gene therapy programs and tau antibody program, including expectations for Voyager’s achievement of preclinical and clinical development milestones for its potential development candidates such as the identification of lead development candidates, IND filings, the initiation of clinical trials, clinical trial enrollment, and the generation of clinical data and proof-of-concept; the potential for an antibody targeting tau to slow the accumulation of tau in the brain of Alzheimer’s patients and for this slowing to offer a clinically significant benefit in some patients; the potential for third-party clinical data to inform Voyager’s clinical development plans; Voyager’s ability to advance gene therapy product candidates under the Neurocrine collaboration; Voyager’s anticipated financial results, including the anticipated receipt by Voyager of revenues or reimbursement payments from collaboration partners; and Voyager’s cash runway and ability to generate sufficient cash resources to enable it to continue its business and operations are forward looking.\n\nAll forward-looking statements are based on estimates and assumptions by Voyager’s management that, although Voyager believes such forward-looking statements to be reasonable, are inherently uncertain and subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected. Such risks and uncertainties include, among others, the expectations and decisions of regulatory authorities; the timing, initiation, conduct and outcomes of Voyager’s preclinical and clinical studies; the availability of data from clinical trials; the availability or commercial potential of product candidates under collaborations; the success of Voyager’s product candidates; the willingness and ability of Voyager's collaboration partners to meet obligations under collaboration agreements with Voyager; the continued development of Voyager’s technology platforms, including Voyager’s TRACER platform and its antibody screening technology; Voyager’s scientific approach and program development progress, and the restricted supply of critical research components; the development by third parties of capsid identification platforms that may be competitive to Voyager’s TRACER capsid discovery platform; Voyager’s ability to create and protect intellectual property rights associated with the TRACER capsid discovery platform, the capsids identified by the platform, and development candidates for Voyager’s pipeline programs; the possibility or the timing of Voyager’s receipt of program reimbursement, development or commercialization milestones, option exercise, and other payments under Voyager’s existing licensing or collaboration agreements; the ability of Voyager to negotiate and complete licensing or collaboration agreements with other parties on terms acceptable to Voyager and the third parties; the success of programs controlled by third-party collaboration partners in which Voyager retains a financial interest; the ability to attract and retain talented directors, employees, and contractors; and the sufficiency of Voyager’s cash resources to fund its operations and pursue its corporate objectives.\n\nThese statements are also subject to a number of material risks and uncertainties that are described in Voyager’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission. All information in the press release is as of the date of this press release, and any forward-looking statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise this information or any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.\n\n**Contacts**\n\nTrista Morrison, NACD.DC, [tmorrison@vygr.com](https://www.globenewswire.com/Tracker?data=_rKLYRFBcU4TDVa3VB3ZG2CWnoZC6cdeb-ua8nHz2Z35JVYWGwqcDFbQhT1tIwzBK_G9PaDH7vl1x6qUacrRxSYPUdvxd2ynnjoYjJejwZs=) Investors: Michael Hencke, [mhencke@kendallir.com](https://www.globenewswire.com/Tracker?data=Jxpq0jr0EBEZ4e8NFwTJWmoKmi8uysKaAG3AFW58T5gkrQBvle-XdIWOnQ0f0Rs4K5WX5J-7pxbpccK1FXp_PjpoWHiPgVe_vhWgEYyVwqk=) Media: Brooke Shenkin, [brooke@scientpr.com](https://www.globenewswire.com/Tracker?data=qvqJHOAdd5TYLrOYB2hfA7n8NVSt_ZuNr2SvX7bIROa2eHnXdn_66mNaF__oCChRxYXEPEmxntWqqXAJW7vkksp9mJmsU6QwCsS0ZJ18TwE=)\n\n**Selected Financial Information**  \n---  \n_($ amounts in thousands, except per share data)_  \n_(Unaudited)_  \n**Three Months Ended** | **Nine Months Ended**  \n**September 30 , ** | **September 30 , **  \n**Statement of Operations Items:** | **2024** | **2023** | **2024** | **2023**  \nCollaboration revenue | $ | 24,629 | $ | 4,614 | $ | 73,723 | $ | 159,947  \nOperating expenses:  \nResearch and development | 30,241 | 25,863 | 91,785 | 66,416  \nGeneral and administrative | 8,168 | 8,258 | 26,926 | 25,580  \nTotal operating expenses | 38,409 | 34,121 | 118,711 | 91,996  \nOperating (loss) income | (13,780 | ) | (29,507 | ) | (44,988 | ) | 67,951  \nTotal other income | 4,779 | 3,429 | 14,554 | 8,570  \n(Loss) income before income taxes | (9,001 | ) | (26,078 | ) | (30,434 | ) | 76,521  \nIncome tax provision (benefit) | 43 | (177 | ) | 81 | 586  \nNet (loss) income | $ | (9,044 | ) | $ | (25,901 | ) | $ | (30,515 | ) | $ | 75,935  \nNet (loss) income per share, basic | $ | (0.16 | ) | $ | (0.59 | ) | $ | (0.53 | ) | $ | 1.85  \nNet (loss) income per share, diluted | $ | (0.16 | ) | $ | (0.59 | ) | $ | (0.53 | ) | $ | 1.78  \nWeighted-average common shares outstanding, basic | 57,851,110 | 43,864,838 | 57,564,413 | 40,962,116  \nWeighted-average common shares outstanding, diluted | 57,851,110 | 43,864,838 | 57,564,413 | 42,610,724  \n  \n**September 30 , ** | **December 31 , **  \n---|---  \n**Selected Balance Sheet Items** | **2024** | **2023**  \nCash, cash equivalents, and marketable securities | $ | 345,360 | $ | 230,875  \nTotal assets | $ | 426,041 | $ | 351,281  \nAccounts payable and accrued expenses | $ | 14,602 | $ | 18,427  \nDeferred revenue | $ | 34,782 | $ | 75,240  \nTotal stockholders’ equity | $ | 330,310 | $ | 236,320  \n  \n![](https://www.globenewswire.com/newsroom/ti?nf=OTI3MTQzMiM2NTc1NzAwIzIwMTg4NDA=)![](https://ml.globenewswire.com/media/YjdhYWRmNjEtOTZkNy00Njg3LThmYWUtMDZhOWMxYzZkMTJiLTEwMzA0MTM=/tiny/Voyager-Therapeutics-Inc-.png)\n\n[![Primary Logo](https://ml.globenewswire.com/media/f775f55a-83dd-4b38-bf92-bb9b588522bd/small/voyager-logos-square-logo-light-png.png)](https://www.globenewswire.com/NewsRoom/AttachmentNg/f775f55a-83dd-4b38-bf92-bb9b588522bd)\n\nSource: Voyager Therapeutics, Inc.\n"
        },
        {
          "title": "Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences",
          "url": "https://ir.voyagertherapeutics.com/news-releases/news-release-details/voyager-therapeutics-present-multiple-upcoming-investor-0",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ![Voyager Therapeutics Inc. Logo](/sites/g/files/knoqqb89791/themes/site/client_site_202/local/images/Voyager_logo_web.png) ](https://www.voyagertherapeutics.com/)\n\n  * [About](https://www.voyagertherapeutics.com/about-overview/)\n  * [Pipeline](https://www.voyagertherapeutics.com/pipeline-overview/)\n  * [Science](https://www.voyagertherapeutics.com/science-overview/)\n  * [Investors](/)\n  * [Careers](https://www.voyagertherapeutics.com/careers-overview/)\n\n\n\n![](/sites/g/files/knoqqb89791/themes/site/client_site_202/local/images/hamburger-icon.png)\n\n![Voyager hamburger close](/sites/g/files/knoqqb89791/themes/site/client_site_202/local/images/Voyager_hamburger_close.png)\n\n[ ![Voyager Therapeutics Inc. Logo](/sites/g/files/knoqqb89791/themes/site/client_site_202/local/images/Voyager_logo_web.png) ](https://www.voyagertherapeutics.com/)\n\nAbout\n\n[Overview](https://www.voyagertherapeutics.com/about-overview/)\n\n[Vision, Mission, & Strategy](https://www.voyagertherapeutics.com/about-vision-mission-strategy/)\n\n[Management Team](https://www.voyagertherapeutics.com/about-leadership/)\n\n[Board of Directors](https://www.voyagertherapeutics.com/about-leadership/#bod)\n\n[Scientific Advisory Board](https://www.voyagertherapeutics.com/about-leadership/#sab)\n\n[Core Values](https://www.voyagertherapeutics.com/about-core-values/)\n\nPipeline\n\n[Overview](https://www.voyagertherapeutics.com/pipeline-overview/)\n\n[• VY7523 for Alzheimer’s](https://www.voyagertherapeutics.com/pipeline-overview/?popup=vy7523)\n\n[• Alzheimer’s early research](https://www.voyagertherapeutics.com/pipeline-overview/?popup=alzheimers)\n\n[• SOD1 for ALS](https://www.voyagertherapeutics.com/pipeline-overview/?popup=sod1)\n\n[Patient Resources](https://www.voyagertherapeutics.com/patient-resources/)\n\n[Partnerships](https://www.voyagertherapeutics.com/science-partnerships/)\n\nScience\n\n[Overview](https://www.voyagertherapeutics.com/science-overview/)\n\n[TRACER Platform](https://www.voyagertherapeutics.com/science-tracer/)\n\n[Non-Viral Delivery](https://www.voyagertherapeutics.com/science-non-viral/)\n\n[Publications & Presentations](https://www.voyagertherapeutics.com/science-publications/)\n\n[Partnerships](https://www.voyagertherapeutics.com/science-partnerships/)\n\nInvestors\n\n[Overview](/)\n\n[Press Releases](/press-releases)\n\n[Events & Presentations](/events-presentations)\n\n[Financials](/financial-information/sec-filings)\n\n[Stock Information](/stock-information/stock-quote)\n\n[Shareholder Services](/shareholder-services/investor-faqs)\n\nCareers\n\n[Overview](https://www.voyagertherapeutics.com/careers-overview/)\n\n[Job Openings](https://boards.greenhouse.io/voyagertherapeutics/)\n\n[Our Community](https://www.voyagertherapeutics.com/careers-culture/)\n\n[Mission & Values](https://www.voyagertherapeutics.com/about-core-values/)\n\n[Benefits](https://www.voyagertherapeutics.com/careers-benefits/)\n\n[Disclosures](https://www.voyagertherapeutics.com/careers-disclosures/)\n\nAbout\n\n[Overview](https://www.voyagertherapeutics.com/about-overview/)\n\n[Vision, Mission, & Strategy](https://www.voyagertherapeutics.com/about-vision-mission-strategy/)\n\n[Management Team](https://www.voyagertherapeutics.com/about-leadership/)\n\n[Board of Directors](https://www.voyagertherapeutics.com/about-leadership/#bod)\n\n[Scientific Advisory Board](https://www.voyagertherapeutics.com/about-leadership/#sab)\n\n[Core Values](https://www.voyagertherapeutics.com/about-core-values/)\n\nPipeline\n\n[Overview](https://www.voyagertherapeutics.com/pipeline-overview/)\n\n[• VY7523 for Alzheimer’s](https://www.voyagertherapeutics.com/pipeline-overview/?popup=vy7523)\n\n[• Alzheimer’s early research](https://www.voyagertherapeutics.com/pipeline-overview/?popup=alzheimers)\n\n[• SOD1 for ALS](https://www.voyagertherapeutics.com/pipeline-overview/?popup=sod1)\n\n[Patient Resources](https://www.voyagertherapeutics.com/patient-resources/)\n\n[Partnerships](https://www.voyagertherapeutics.com/science-partnerships/)\n\nScience\n\n[Overview](https://www.voyagertherapeutics.com/science-overview/)\n\n[TRACER Platform](https://www.voyagertherapeutics.com/science-tracer/)\n\n[Non-Viral Delivery](https://www.voyagertherapeutics.com/science-non-viral/)\n\n[Publications & Presentations](https://www.voyagertherapeutics.com/science-publications/)\n\n[Partnerships](https://www.voyagertherapeutics.com/science-partnerships/)\n\nInvestors\n\n[Overview](/)\n\n[Press Releases](/press-releases)\n\n[Events & Presentations](/events-presentations)\n\n[Financials](/financial-information/sec-filings)\n\n[Stock Information](/stock-information/stock-quote)\n\n[Shareholder Services](/shareholder-services/investor-faqs)\n\nCareers\n\n[Overview](https://www.voyagertherapeutics.com/careers-overview/)\n\n[Job Openings](https://boards.greenhouse.io/voyagertherapeutics/)\n\n[Our Community](https://www.voyagertherapeutics.com/careers-culture/)\n\n[Mission & Values](https://www.voyagertherapeutics.com/about-core-values/)\n\n[Benefits](https://www.voyagertherapeutics.com/careers-benefits/)\n\n[Disclosures](https://www.voyagertherapeutics.com/careers-disclosures/)\n\nSearch for:\n\n# Release Details\n\n  * [Overview](/ \"Main Investor Relations Page\")\n  * [Press Releases](/press-releases)\n  * [Events & Presentations](/events-presentations)\n  * [Financials](/financial-information/sec-filings)\n    * [SEC Filings](/financial-information/sec-filings)\n    * [Annual Reports](/financial-information/annual-reports)\n  * [Stock Information](/stock-information/stock-quote)\n    * [Stock Quote & Chart](/stock-information/stock-quote)\n  * [Corporate Governance]()\n    * [Leadership Team](https://www.voyagertherapeutics.com/about-leadership/#managementteam)\n    * [Board of Directors](https://www.voyagertherapeutics.com/about-leadership/#bod)\n    * [Scientific Advisors](https://www.voyagertherapeutics.com/about-leadership/#sab \"Code of Conduct\")\n    * [Committee Composition](/corporate-governance/committee-composition)\n    * [Documents & Charters](/corporate-governance/highlights)\n    * [Contact the Board](/corporate-governance/contact-the-board)\n  * [Shareholder Services](/shareholder-services/investor-faqs)\n    * [Investor FAQs](/shareholder-services/investor-faqs)\n    * [Analyst Coverage](/shareholder-services/analyst-coverage)\n    * [Contact Us](/shareholder-services/document-request)\n    * [Email Alerts](/shareholder-services/email-alerts)\n\n\n\n## \n\nVoyager Therapeutics to Present at Multiple Upcoming Investor Conferences\n\n11/06/24\n\n[PDF Version](/node/12166/pdf)\n\nLEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the Company will participate in multiple upcoming investor conferences:\n\n  * Truist Securities BioPharma Symposium, in New York City, including a panel discussion on Genetic Medicines at 1:45 p.m. ET on November 7, 2024\n  * Guggenheim Inaugural Healthcare Innovation Conference*, in Boston, including a fireside chat at 2:00 p.m. ET on November 13, 2024\n  * B. Riley Securities’ Next-Gen Tissue Delivery Modalities Virtual Summit, virtual, including a fireside chat at 1:30 p.m. ET on November 14, 2024\n  * Stifel 2024 Healthcare Conference*, in New York City, including a fireside chat at 9:45 a.m. ET on November 18, 2024\n\n\n\nFor the conferences denoted by an asterisk, webcasts will be available and may be accessed from the Investors section of Voyager’s website at [ir.voyagertherapeutics.com](https://www.globenewswire.com/Tracker?data=cUJfprOiKRMROwi4VzbfHmfdygzhXPFltTDodozpQwKwijMsUVq1fmfYRcuZanyUKCowH2i2-ZFT72ib8BkVYG3oyYFgBVIj0nINBwNfjzCV15z_bd2w2QV62-_nX39J). A replay of any webcasts will be archived on the Company's website for at least 30 days.\n\n**About Voyager Therapeutics**Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more information, visit [www.voyagertherapeutics.com](https://www.globenewswire.com/Tracker?data=8HD-NZaYTzbNIQtz99i2FCSGZE6gPeH8gH_5ZUq5umJBN5U1jVS3znvhf2DWonkt8qAte9o3Ck86teW4_mEe-lg1UAx2F9_9gJzM7zn_6c88Tgx3a7AV1tbuOpJkUo1P).\n\n_Voyager Therapeutics ® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc._\n\n**Contacts** Trista Morrison, NACD.DC, [tmorrison@vygr.com](https://www.globenewswire.com/Tracker?data=z5-too5Ie4fIHepZVqF7Eb5jQA6ysqk5R3FK28KyeMAuKVYO21opd7iipdo0VL5I1AvPf0Yo3klD5itEGCsnbc5f-QgOadtSPChdeiGBZC4=) Investors: Mike Hencke, [mhencke@kendallir.com](https://www.globenewswire.com/Tracker?data=ZrLdDIhmh4gYaTK6QspjqdNjz3J9j2h-TjvF7oAkUh7Jovk1hr7bD0TCcPyxw9Zn0cgLZ0SuGCSBOb9DOgdkHOgPPp8_dzF7wrCWE_TIXZE=)Media: Brooke Shenkin, [brooke@scientpr.com](https://www.globenewswire.com/Tracker?data=q66dYuYdvE8mqAv8CDwNzfCzjbtRnHxlhOiQ0QsAIMRF25gu0nEKlubuq7HRxkMI-nSoRxN9vXyyU-tRKbaMSR6_5TXrbp9cwpt76RADX94=)\n\n![](https://www.globenewswire.com/newsroom/ti?nf=OTI2ODEzMiM2NTY2OTU5IzIwMTg4NDA=)![](https://ml.globenewswire.com/media/YzkxMGVkMzctODZkOC00OWVjLTg0ZGQtYzMwMTYzZDNkZDI2LTEwMzA0MTM=/tiny/Voyager-Therapeutics-Inc-.png)\n\n[![Primary Logo](https://ml.globenewswire.com/media/f775f55a-83dd-4b38-bf92-bb9b588522bd/small/voyager-logos-square-logo-light-png.png)](https://www.globenewswire.com/NewsRoom/AttachmentNg/f775f55a-83dd-4b38-bf92-bb9b588522bd)\n\nSource: Voyager Therapeutics, Inc.\n"
        }
      ]
    },
    {
      "section_name": "Events & Presentations",
      "links": [
        {
          "title": "Stifel 2024 Healthcare Conference",
          "url": "https://ir.voyagertherapeutics.com/events/event-details/stifel-2024-healthcare-conference",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ![Voyager Therapeutics Inc. Logo](/sites/g/files/knoqqb89791/themes/site/client_site_202/local/images/Voyager_logo_web.png) ](https://www.voyagertherapeutics.com/)\n\n  * [About](https://www.voyagertherapeutics.com/about-overview/)\n  * [Pipeline](https://www.voyagertherapeutics.com/pipeline-overview/)\n  * [Science](https://www.voyagertherapeutics.com/science-overview/)\n  * [Investors](/)\n  * [Careers](https://www.voyagertherapeutics.com/careers-overview/)\n\n\n\n![](/sites/g/files/knoqqb89791/themes/site/client_site_202/local/images/hamburger-icon.png)\n\n![Voyager hamburger close](/sites/g/files/knoqqb89791/themes/site/client_site_202/local/images/Voyager_hamburger_close.png)\n\n[ ![Voyager Therapeutics Inc. Logo](/sites/g/files/knoqqb89791/themes/site/client_site_202/local/images/Voyager_logo_web.png) ](https://www.voyagertherapeutics.com/)\n\nAbout\n\n[Overview](https://www.voyagertherapeutics.com/about-overview/)\n\n[Vision, Mission, & Strategy](https://www.voyagertherapeutics.com/about-vision-mission-strategy/)\n\n[Management Team](https://www.voyagertherapeutics.com/about-leadership/)\n\n[Board of Directors](https://www.voyagertherapeutics.com/about-leadership/#bod)\n\n[Scientific Advisory Board](https://www.voyagertherapeutics.com/about-leadership/#sab)\n\n[Core Values](https://www.voyagertherapeutics.com/about-core-values/)\n\nPipeline\n\n[Overview](https://www.voyagertherapeutics.com/pipeline-overview/)\n\n[• VY7523 for Alzheimer’s](https://www.voyagertherapeutics.com/pipeline-overview/?popup=vy7523)\n\n[• Alzheimer’s early research](https://www.voyagertherapeutics.com/pipeline-overview/?popup=alzheimers)\n\n[• SOD1 for ALS](https://www.voyagertherapeutics.com/pipeline-overview/?popup=sod1)\n\n[Patient Resources](https://www.voyagertherapeutics.com/patient-resources/)\n\n[Partnerships](https://www.voyagertherapeutics.com/science-partnerships/)\n\nScience\n\n[Overview](https://www.voyagertherapeutics.com/science-overview/)\n\n[TRACER Platform](https://www.voyagertherapeutics.com/science-tracer/)\n\n[Non-Viral Delivery](https://www.voyagertherapeutics.com/science-non-viral/)\n\n[Publications & Presentations](https://www.voyagertherapeutics.com/science-publications/)\n\n[Partnerships](https://www.voyagertherapeutics.com/science-partnerships/)\n\nInvestors\n\n[Overview](/)\n\n[Press Releases](/press-releases)\n\n[Events & Presentations](/events-presentations)\n\n[Financials](/financial-information/sec-filings)\n\n[Stock Information](/stock-information/stock-quote)\n\n[Shareholder Services](/shareholder-services/investor-faqs)\n\nCareers\n\n[Overview](https://www.voyagertherapeutics.com/careers-overview/)\n\n[Job Openings](https://boards.greenhouse.io/voyagertherapeutics/)\n\n[Our Community](https://www.voyagertherapeutics.com/careers-culture/)\n\n[Mission & Values](https://www.voyagertherapeutics.com/about-core-values/)\n\n[Benefits](https://www.voyagertherapeutics.com/careers-benefits/)\n\n[Disclosures](https://www.voyagertherapeutics.com/careers-disclosures/)\n\nAbout\n\n[Overview](https://www.voyagertherapeutics.com/about-overview/)\n\n[Vision, Mission, & Strategy](https://www.voyagertherapeutics.com/about-vision-mission-strategy/)\n\n[Management Team](https://www.voyagertherapeutics.com/about-leadership/)\n\n[Board of Directors](https://www.voyagertherapeutics.com/about-leadership/#bod)\n\n[Scientific Advisory Board](https://www.voyagertherapeutics.com/about-leadership/#sab)\n\n[Core Values](https://www.voyagertherapeutics.com/about-core-values/)\n\nPipeline\n\n[Overview](https://www.voyagertherapeutics.com/pipeline-overview/)\n\n[• VY7523 for Alzheimer’s](https://www.voyagertherapeutics.com/pipeline-overview/?popup=vy7523)\n\n[• Alzheimer’s early research](https://www.voyagertherapeutics.com/pipeline-overview/?popup=alzheimers)\n\n[• SOD1 for ALS](https://www.voyagertherapeutics.com/pipeline-overview/?popup=sod1)\n\n[Patient Resources](https://www.voyagertherapeutics.com/patient-resources/)\n\n[Partnerships](https://www.voyagertherapeutics.com/science-partnerships/)\n\nScience\n\n[Overview](https://www.voyagertherapeutics.com/science-overview/)\n\n[TRACER Platform](https://www.voyagertherapeutics.com/science-tracer/)\n\n[Non-Viral Delivery](https://www.voyagertherapeutics.com/science-non-viral/)\n\n[Publications & Presentations](https://www.voyagertherapeutics.com/science-publications/)\n\n[Partnerships](https://www.voyagertherapeutics.com/science-partnerships/)\n\nInvestors\n\n[Overview](/)\n\n[Press Releases](/press-releases)\n\n[Events & Presentations](/events-presentations)\n\n[Financials](/financial-information/sec-filings)\n\n[Stock Information](/stock-information/stock-quote)\n\n[Shareholder Services](/shareholder-services/investor-faqs)\n\nCareers\n\n[Overview](https://www.voyagertherapeutics.com/careers-overview/)\n\n[Job Openings](https://boards.greenhouse.io/voyagertherapeutics/)\n\n[Our Community](https://www.voyagertherapeutics.com/careers-culture/)\n\n[Mission & Values](https://www.voyagertherapeutics.com/about-core-values/)\n\n[Benefits](https://www.voyagertherapeutics.com/careers-benefits/)\n\n[Disclosures](https://www.voyagertherapeutics.com/careers-disclosures/)\n\nSearch for:\n\n# Event Details\n\n  * [Overview](/ \"Main Investor Relations Page\")\n  * [Press Releases](/press-releases)\n  * [Events & Presentations](/events-presentations)\n  * [Financials](/financial-information/sec-filings)\n    * [SEC Filings](/financial-information/sec-filings)\n    * [Annual Reports](/financial-information/annual-reports)\n  * [Stock Information](/stock-information/stock-quote)\n    * [Stock Quote & Chart](/stock-information/stock-quote)\n  * [Corporate Governance]()\n    * [Leadership Team](https://www.voyagertherapeutics.com/about-leadership/#managementteam)\n    * [Board of Directors](https://www.voyagertherapeutics.com/about-leadership/#bod)\n    * [Scientific Advisors](https://www.voyagertherapeutics.com/about-leadership/#sab \"Code of Conduct\")\n    * [Committee Composition](/corporate-governance/committee-composition)\n    * [Documents & Charters](/corporate-governance/highlights)\n    * [Contact the Board](/corporate-governance/contact-the-board)\n  * [Shareholder Services](/shareholder-services/investor-faqs)\n    * [Investor FAQs](/shareholder-services/investor-faqs)\n    * [Analyst Coverage](/shareholder-services/analyst-coverage)\n    * [Contact Us](/shareholder-services/document-request)\n    * [Email Alerts](/shareholder-services/email-alerts)\n\n\n\n## Stifel 2024 Healthcare Conference\n\n11/17/24 9:45 AM EST\n\n[Click here for the webcast](https://wsw.com/webcast/stifel96/register.aspx?conf=stifel96&page=vygr&url=https%3A//wsw.com/webcast/stifel96/vygr/2141040)\n"
        },
        {
          "title": "Guggenheim Inaugural Healthcare Innovation Conference",
          "url": "https://ir.voyagertherapeutics.com/events/event-details/guggenheim-inaugural-healthcare-innovation-conference",
          "content": null
        },
        {
          "title": "Q3 2024 Voyager Therapeutics, Inc. Earnings Conference Call",
          "url": "https://ir.voyagertherapeutics.com/events/event-details/q3-2024-voyager-therapeutics-inc-earnings-conference-call",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ![Voyager Therapeutics Inc. Logo](/sites/g/files/knoqqb89791/themes/site/client_site_202/local/images/Voyager_logo_web.png) ](https://www.voyagertherapeutics.com/)\n\n  * [About](https://www.voyagertherapeutics.com/about-overview/)\n  * [Pipeline](https://www.voyagertherapeutics.com/pipeline-overview/)\n  * [Science](https://www.voyagertherapeutics.com/science-overview/)\n  * [Investors](/)\n  * [Careers](https://www.voyagertherapeutics.com/careers-overview/)\n\n\n\n![](/sites/g/files/knoqqb89791/themes/site/client_site_202/local/images/hamburger-icon.png)\n\n![Voyager hamburger close](/sites/g/files/knoqqb89791/themes/site/client_site_202/local/images/Voyager_hamburger_close.png)\n\n[ ![Voyager Therapeutics Inc. Logo](/sites/g/files/knoqqb89791/themes/site/client_site_202/local/images/Voyager_logo_web.png) ](https://www.voyagertherapeutics.com/)\n\nAbout\n\n[Overview](https://www.voyagertherapeutics.com/about-overview/)\n\n[Vision, Mission, & Strategy](https://www.voyagertherapeutics.com/about-vision-mission-strategy/)\n\n[Management Team](https://www.voyagertherapeutics.com/about-leadership/)\n\n[Board of Directors](https://www.voyagertherapeutics.com/about-leadership/#bod)\n\n[Scientific Advisory Board](https://www.voyagertherapeutics.com/about-leadership/#sab)\n\n[Core Values](https://www.voyagertherapeutics.com/about-core-values/)\n\nPipeline\n\n[Overview](https://www.voyagertherapeutics.com/pipeline-overview/)\n\n[• VY7523 for Alzheimer’s](https://www.voyagertherapeutics.com/pipeline-overview/?popup=vy7523)\n\n[• Alzheimer’s early research](https://www.voyagertherapeutics.com/pipeline-overview/?popup=alzheimers)\n\n[• SOD1 for ALS](https://www.voyagertherapeutics.com/pipeline-overview/?popup=sod1)\n\n[Patient Resources](https://www.voyagertherapeutics.com/patient-resources/)\n\n[Partnerships](https://www.voyagertherapeutics.com/science-partnerships/)\n\nScience\n\n[Overview](https://www.voyagertherapeutics.com/science-overview/)\n\n[TRACER Platform](https://www.voyagertherapeutics.com/science-tracer/)\n\n[Non-Viral Delivery](https://www.voyagertherapeutics.com/science-non-viral/)\n\n[Publications & Presentations](https://www.voyagertherapeutics.com/science-publications/)\n\n[Partnerships](https://www.voyagertherapeutics.com/science-partnerships/)\n\nInvestors\n\n[Overview](/)\n\n[Press Releases](/press-releases)\n\n[Events & Presentations](/events-presentations)\n\n[Financials](/financial-information/sec-filings)\n\n[Stock Information](/stock-information/stock-quote)\n\n[Shareholder Services](/shareholder-services/investor-faqs)\n\nCareers\n\n[Overview](https://www.voyagertherapeutics.com/careers-overview/)\n\n[Job Openings](https://boards.greenhouse.io/voyagertherapeutics/)\n\n[Our Community](https://www.voyagertherapeutics.com/careers-culture/)\n\n[Mission & Values](https://www.voyagertherapeutics.com/about-core-values/)\n\n[Benefits](https://www.voyagertherapeutics.com/careers-benefits/)\n\n[Disclosures](https://www.voyagertherapeutics.com/careers-disclosures/)\n\nAbout\n\n[Overview](https://www.voyagertherapeutics.com/about-overview/)\n\n[Vision, Mission, & Strategy](https://www.voyagertherapeutics.com/about-vision-mission-strategy/)\n\n[Management Team](https://www.voyagertherapeutics.com/about-leadership/)\n\n[Board of Directors](https://www.voyagertherapeutics.com/about-leadership/#bod)\n\n[Scientific Advisory Board](https://www.voyagertherapeutics.com/about-leadership/#sab)\n\n[Core Values](https://www.voyagertherapeutics.com/about-core-values/)\n\nPipeline\n\n[Overview](https://www.voyagertherapeutics.com/pipeline-overview/)\n\n[• VY7523 for Alzheimer’s](https://www.voyagertherapeutics.com/pipeline-overview/?popup=vy7523)\n\n[• Alzheimer’s early research](https://www.voyagertherapeutics.com/pipeline-overview/?popup=alzheimers)\n\n[• SOD1 for ALS](https://www.voyagertherapeutics.com/pipeline-overview/?popup=sod1)\n\n[Patient Resources](https://www.voyagertherapeutics.com/patient-resources/)\n\n[Partnerships](https://www.voyagertherapeutics.com/science-partnerships/)\n\nScience\n\n[Overview](https://www.voyagertherapeutics.com/science-overview/)\n\n[TRACER Platform](https://www.voyagertherapeutics.com/science-tracer/)\n\n[Non-Viral Delivery](https://www.voyagertherapeutics.com/science-non-viral/)\n\n[Publications & Presentations](https://www.voyagertherapeutics.com/science-publications/)\n\n[Partnerships](https://www.voyagertherapeutics.com/science-partnerships/)\n\nInvestors\n\n[Overview](/)\n\n[Press Releases](/press-releases)\n\n[Events & Presentations](/events-presentations)\n\n[Financials](/financial-information/sec-filings)\n\n[Stock Information](/stock-information/stock-quote)\n\n[Shareholder Services](/shareholder-services/investor-faqs)\n\nCareers\n\n[Overview](https://www.voyagertherapeutics.com/careers-overview/)\n\n[Job Openings](https://boards.greenhouse.io/voyagertherapeutics/)\n\n[Our Community](https://www.voyagertherapeutics.com/careers-culture/)\n\n[Mission & Values](https://www.voyagertherapeutics.com/about-core-values/)\n\n[Benefits](https://www.voyagertherapeutics.com/careers-benefits/)\n\n[Disclosures](https://www.voyagertherapeutics.com/careers-disclosures/)\n\nSearch for:\n\n# Event Details\n\n  * [Overview](/ \"Main Investor Relations Page\")\n  * [Press Releases](/press-releases)\n  * [Events & Presentations](/events-presentations)\n  * [Financials](/financial-information/sec-filings)\n    * [SEC Filings](/financial-information/sec-filings)\n    * [Annual Reports](/financial-information/annual-reports)\n  * [Stock Information](/stock-information/stock-quote)\n    * [Stock Quote & Chart](/stock-information/stock-quote)\n  * [Corporate Governance]()\n    * [Leadership Team](https://www.voyagertherapeutics.com/about-leadership/#managementteam)\n    * [Board of Directors](https://www.voyagertherapeutics.com/about-leadership/#bod)\n    * [Scientific Advisors](https://www.voyagertherapeutics.com/about-leadership/#sab \"Code of Conduct\")\n    * [Committee Composition](/corporate-governance/committee-composition)\n    * [Documents & Charters](/corporate-governance/highlights)\n    * [Contact the Board](/corporate-governance/contact-the-board)\n  * [Shareholder Services](/shareholder-services/investor-faqs)\n    * [Investor FAQs](/shareholder-services/investor-faqs)\n    * [Analyst Coverage](/shareholder-services/analyst-coverage)\n    * [Contact Us](/shareholder-services/document-request)\n    * [Email Alerts](/shareholder-services/email-alerts)\n\n\n\n## Q3 2024 Voyager Therapeutics, Inc. Earnings Conference Call\n\n11/12/24 4:30 PM EST\n\n[Click here for the webcast](https://edge.media-server.com/mmc/p/t8v39djs)\n"
        }
      ]
    },
    {
      "section_name": "Financial Reports",
      "links": [
        {
          "title": "SEC Filings",
          "url": "https://ir.voyagertherapeutics.com/financial-information/sec-filings",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ![Voyager Therapeutics Inc. Logo](/sites/g/files/knoqqb89791/themes/site/client_site_202/local/images/Voyager_logo_web.png) ](https://www.voyagertherapeutics.com/)\n\n  * [About](https://www.voyagertherapeutics.com/about-overview/)\n  * [Pipeline](https://www.voyagertherapeutics.com/pipeline-overview/)\n  * [Science](https://www.voyagertherapeutics.com/science-overview/)\n  * [Investors](/)\n  * [Careers](https://www.voyagertherapeutics.com/careers-overview/)\n\n\n\n![](/sites/g/files/knoqqb89791/themes/site/client_site_202/local/images/hamburger-icon.png)\n\n![Voyager hamburger close](/sites/g/files/knoqqb89791/themes/site/client_site_202/local/images/Voyager_hamburger_close.png)\n\n[ ![Voyager Therapeutics Inc. Logo](/sites/g/files/knoqqb89791/themes/site/client_site_202/local/images/Voyager_logo_web.png) ](https://www.voyagertherapeutics.com/)\n\nAbout\n\n[Overview](https://www.voyagertherapeutics.com/about-overview/)\n\n[Vision, Mission, & Strategy](https://www.voyagertherapeutics.com/about-vision-mission-strategy/)\n\n[Management Team](https://www.voyagertherapeutics.com/about-leadership/)\n\n[Board of Directors](https://www.voyagertherapeutics.com/about-leadership/#bod)\n\n[Scientific Advisory Board](https://www.voyagertherapeutics.com/about-leadership/#sab)\n\n[Core Values](https://www.voyagertherapeutics.com/about-core-values/)\n\nPipeline\n\n[Overview](https://www.voyagertherapeutics.com/pipeline-overview/)\n\n[• VY7523 for Alzheimer’s](https://www.voyagertherapeutics.com/pipeline-overview/?popup=vy7523)\n\n[• Alzheimer’s early research](https://www.voyagertherapeutics.com/pipeline-overview/?popup=alzheimers)\n\n[• SOD1 for ALS](https://www.voyagertherapeutics.com/pipeline-overview/?popup=sod1)\n\n[Patient Resources](https://www.voyagertherapeutics.com/patient-resources/)\n\n[Partnerships](https://www.voyagertherapeutics.com/science-partnerships/)\n\nScience\n\n[Overview](https://www.voyagertherapeutics.com/science-overview/)\n\n[TRACER Platform](https://www.voyagertherapeutics.com/science-tracer/)\n\n[Non-Viral Delivery](https://www.voyagertherapeutics.com/science-non-viral/)\n\n[Publications & Presentations](https://www.voyagertherapeutics.com/science-publications/)\n\n[Partnerships](https://www.voyagertherapeutics.com/science-partnerships/)\n\nInvestors\n\n[Overview](/)\n\n[Press Releases](/press-releases)\n\n[Events & Presentations](/events-presentations)\n\n[Financials](/financial-information/sec-filings)\n\n[Stock Information](/stock-information/stock-quote)\n\n[Shareholder Services](/shareholder-services/investor-faqs)\n\nCareers\n\n[Overview](https://www.voyagertherapeutics.com/careers-overview/)\n\n[Job Openings](https://boards.greenhouse.io/voyagertherapeutics/)\n\n[Our Community](https://www.voyagertherapeutics.com/careers-culture/)\n\n[Mission & Values](https://www.voyagertherapeutics.com/about-core-values/)\n\n[Benefits](https://www.voyagertherapeutics.com/careers-benefits/)\n\n[Disclosures](https://www.voyagertherapeutics.com/careers-disclosures/)\n\nAbout\n\n[Overview](https://www.voyagertherapeutics.com/about-overview/)\n\n[Vision, Mission, & Strategy](https://www.voyagertherapeutics.com/about-vision-mission-strategy/)\n\n[Management Team](https://www.voyagertherapeutics.com/about-leadership/)\n\n[Board of Directors](https://www.voyagertherapeutics.com/about-leadership/#bod)\n\n[Scientific Advisory Board](https://www.voyagertherapeutics.com/about-leadership/#sab)\n\n[Core Values](https://www.voyagertherapeutics.com/about-core-values/)\n\nPipeline\n\n[Overview](https://www.voyagertherapeutics.com/pipeline-overview/)\n\n[• VY7523 for Alzheimer’s](https://www.voyagertherapeutics.com/pipeline-overview/?popup=vy7523)\n\n[• Alzheimer’s early research](https://www.voyagertherapeutics.com/pipeline-overview/?popup=alzheimers)\n\n[• SOD1 for ALS](https://www.voyagertherapeutics.com/pipeline-overview/?popup=sod1)\n\n[Patient Resources](https://www.voyagertherapeutics.com/patient-resources/)\n\n[Partnerships](https://www.voyagertherapeutics.com/science-partnerships/)\n\nScience\n\n[Overview](https://www.voyagertherapeutics.com/science-overview/)\n\n[TRACER Platform](https://www.voyagertherapeutics.com/science-tracer/)\n\n[Non-Viral Delivery](https://www.voyagertherapeutics.com/science-non-viral/)\n\n[Publications & Presentations](https://www.voyagertherapeutics.com/science-publications/)\n\n[Partnerships](https://www.voyagertherapeutics.com/science-partnerships/)\n\nInvestors\n\n[Overview](/)\n\n[Press Releases](/press-releases)\n\n[Events & Presentations](/events-presentations)\n\n[Financials](/financial-information/sec-filings)\n\n[Stock Information](/stock-information/stock-quote)\n\n[Shareholder Services](/shareholder-services/investor-faqs)\n\nCareers\n\n[Overview](https://www.voyagertherapeutics.com/careers-overview/)\n\n[Job Openings](https://boards.greenhouse.io/voyagertherapeutics/)\n\n[Our Community](https://www.voyagertherapeutics.com/careers-culture/)\n\n[Mission & Values](https://www.voyagertherapeutics.com/about-core-values/)\n\n[Benefits](https://www.voyagertherapeutics.com/careers-benefits/)\n\n[Disclosures](https://www.voyagertherapeutics.com/careers-disclosures/)\n\nSearch for:\n\n# SEC Filings\n\n  * [Overview](/ \"Main Investor Relations Page\")\n  * [Press Releases](/press-releases)\n  * [Events & Presentations](/events-presentations)\n  * [Financials](/financial-information/sec-filings)\n    * [SEC Filings](/financial-information/sec-filings)\n    * [Annual Reports](/financial-information/annual-reports)\n  * [Stock Information](/stock-information/stock-quote)\n    * [Stock Quote & Chart](/stock-information/stock-quote)\n  * [Corporate Governance]()\n    * [Leadership Team](https://www.voyagertherapeutics.com/about-leadership/#managementteam)\n    * [Board of Directors](https://www.voyagertherapeutics.com/about-leadership/#bod)\n    * [Scientific Advisors](https://www.voyagertherapeutics.com/about-leadership/#sab \"Code of Conduct\")\n    * [Committee Composition](/corporate-governance/committee-composition)\n    * [Documents & Charters](/corporate-governance/highlights)\n    * [Contact the Board](/corporate-governance/contact-the-board)\n  * [Shareholder Services](/shareholder-services/investor-faqs)\n    * [Investor FAQs](/shareholder-services/investor-faqs)\n    * [Analyst Coverage](/shareholder-services/analyst-coverage)\n    * [Contact Us](/shareholder-services/document-request)\n    * [Email Alerts](/shareholder-services/email-alerts)\n\n\n\nGroup 3,4,5Annual FilingsCurrent ReportsMergers & AcquisitionsOtherProxy FilingsQuarterly FilingsRegistration Statements\n\nFiling year All2024202320222021202020192018201720162015\n\nAll\n\n[Filing Date](?items_per_page=10&order=field_nir_sec_date_filed&sort=asc \"Sort By Filing Date\") | [Form](?items_per_page=10&order=field_nir_sec_form&sort=asc \"Sort By Form\") | [Description](?items_per_page=10&order=field_nir_sec_description&sort=asc \"Sort By Description\") | Filing Group | View  \n---|---|---|---|---  \n11/14/24 |  [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0001172661-24-005316) |  An amendment to the SC 13G filing |  Other |  [0001172661-24-005316.rtf](/static-files/6c17c245-db79-4dc8-a02c-b47441351b85) [0001172661-24-005316.xls](/static-files/ab2a2344-ca2e-43b2-b836-621815b438d3) [0001172661-24-005316.pdf](/static-files/47a24d6e-6748-4ec8-a0fb-a6b2f452282f)  \n11/14/24 |  [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0000935836-24-000721) |  An amendment to the SC 13G filing |  Other |  [0000935836-24-000721.rtf](/static-files/19e4d514-15c7-4c0b-84a5-ad55f21d9e6f) [0000935836-24-000721.xls](/static-files/c6e749f6-2551-4464-ba55-512928754b12) [0000935836-24-000721.pdf](/static-files/541f7275-c5ad-4c59-8d62-44c6e419d5ad)  \n11/12/24 |  [8-K](/sec-filings/sec-filing/8-k/0001558370-24-015299) |  Report of unscheduled material events or corporate event |  Current Reports |  [0001558370-24-015299.rtf](/static-files/a702e90f-bdd6-461b-b737-d56752f0eb10) [0001558370-24-015299.xls](/static-files/1e953589-29da-4c10-8da4-da47697f5f48) [0001558370-24-015299.pdf](/static-files/163f40a9-d601-4819-b1e1-0b0efb58bc25) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0001558370-24-015299)  \n11/12/24 |  [10-Q](/sec-filings/sec-filing/10-q/0001558370-24-015304) |  Quarterly report which provides a continuing view of a company's financial position |  Quarterly Filings |  [0001558370-24-015304.rtf](/static-files/af74f543-9ff0-4bf3-94d4-e3fb9e957dde) [0001558370-24-015304.xls](/static-files/ae3ff426-ab29-4611-9557-019bfc7ac70f) [0001558370-24-015304.pdf](/static-files/66783910-bf51-4513-acb4-a5fc63a6b954) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-q/0001558370-24-015304)  \n10/03/24 |  [4](/sec-filings/sec-filing/4/0001104659-24-105885) |  Statement of changes in beneficial ownership of securities |  3,4,5 |  [0001104659-24-105885.rtf](/static-files/fea29c69-beaf-49e9-a2ca-c4375e12d5bd) [0001104659-24-105885.xls](/static-files/cc728b3d-eea3-486e-899d-17a685762adf) [0001104659-24-105885.pdf](/static-files/54ed3458-a8cc-4159-affc-b0ca151ebf97)  \n10/02/24 |  [4](/sec-filings/sec-filing/4/0001104659-24-105438) |  Statement of changes in beneficial ownership of securities |  3,4,5 |  [0001104659-24-105438.rtf](/static-files/9d0d6781-e695-4f7e-936c-ae6fbd9d964e) [0001104659-24-105438.xls](/static-files/ade3a42d-b3ff-4405-9e87-d2685a26453c) [0001104659-24-105438.pdf](/static-files/7c95a82a-9a3c-46d3-b7f8-77acde59af06)  \n10/02/24 |  [144](/sec-filings/sec-filing/144/0001959173-24-006837) |  Filed by \"insiders\" prior intended sale of restricted stock. Non-EDGAR filing |  Other |  [0001959173-24-006837.rtf](/static-files/7f372d8e-8f83-4f6b-bb66-285f8994c8ec) [0001959173-24-006837.pdf](/static-files/b78ace2b-8468-4563-9ce8-649a14f707ef)  \n09/05/24 |  [8-K](/sec-filings/sec-filing/8-k/0001104659-24-097152) |  Report of unscheduled material events or corporate event |  Current Reports |  [0001104659-24-097152.rtf](/static-files/d9c2ff65-7d1e-406c-ba97-20ef692b2910) [0001104659-24-097152.xls](/static-files/ec1ad025-d804-4c35-bf55-fb9fffb1e7a6) [0001104659-24-097152.pdf](/static-files/70bdd6ca-0c56-499b-b3d6-343f82ee9d6f) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0001104659-24-097152)  \n08/07/24 |  [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0001086364-24-008406) |  An amendment to the SC 13G filing |  Other |  [0001086364-24-008406.rtf](/static-files/0c3ed767-7853-4daa-9387-fe598fa1bb7f) [0001086364-24-008406.pdf](/static-files/94d97765-b598-43ee-bf69-5c8bf30876fb)  \n08/06/24 |  [8-K](/sec-filings/sec-filing/8-k/0001558370-24-011071) |  Report of unscheduled material events or corporate event |  Current Reports |  [0001558370-24-011071.rtf](/static-files/33f1c132-53ef-40bf-954f-26c6a6c24a71) [0001558370-24-011071.xls](/static-files/8424b5a7-1bb0-4556-8a92-2b8190176821) [0001558370-24-011071.pdf](/static-files/7c6f94bd-7ed6-4508-9780-d1e839c055ec) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0001558370-24-011071)  \n  \nData provided by [Kaleidoscope](https://www.kscope.io).\n"
        },
        {
          "title": "Annual Reports",
          "url": "https://ir.voyagertherapeutics.com/financial-information/annual-reports",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ![Voyager Therapeutics Inc. Logo](/sites/g/files/knoqqb89791/themes/site/client_site_202/local/images/Voyager_logo_web.png) ](https://www.voyagertherapeutics.com/)\n\n  * [About](https://www.voyagertherapeutics.com/about-overview/)\n  * [Pipeline](https://www.voyagertherapeutics.com/pipeline-overview/)\n  * [Science](https://www.voyagertherapeutics.com/science-overview/)\n  * [Investors](/)\n  * [Careers](https://www.voyagertherapeutics.com/careers-overview/)\n\n\n\n![](/sites/g/files/knoqqb89791/themes/site/client_site_202/local/images/hamburger-icon.png)\n\n![Voyager hamburger close](/sites/g/files/knoqqb89791/themes/site/client_site_202/local/images/Voyager_hamburger_close.png)\n\n[ ![Voyager Therapeutics Inc. Logo](/sites/g/files/knoqqb89791/themes/site/client_site_202/local/images/Voyager_logo_web.png) ](https://www.voyagertherapeutics.com/)\n\nAbout\n\n[Overview](https://www.voyagertherapeutics.com/about-overview/)\n\n[Vision, Mission, & Strategy](https://www.voyagertherapeutics.com/about-vision-mission-strategy/)\n\n[Management Team](https://www.voyagertherapeutics.com/about-leadership/)\n\n[Board of Directors](https://www.voyagertherapeutics.com/about-leadership/#bod)\n\n[Scientific Advisory Board](https://www.voyagertherapeutics.com/about-leadership/#sab)\n\n[Core Values](https://www.voyagertherapeutics.com/about-core-values/)\n\nPipeline\n\n[Overview](https://www.voyagertherapeutics.com/pipeline-overview/)\n\n[• VY7523 for Alzheimer’s](https://www.voyagertherapeutics.com/pipeline-overview/?popup=vy7523)\n\n[• Alzheimer’s early research](https://www.voyagertherapeutics.com/pipeline-overview/?popup=alzheimers)\n\n[• SOD1 for ALS](https://www.voyagertherapeutics.com/pipeline-overview/?popup=sod1)\n\n[Patient Resources](https://www.voyagertherapeutics.com/patient-resources/)\n\n[Partnerships](https://www.voyagertherapeutics.com/science-partnerships/)\n\nScience\n\n[Overview](https://www.voyagertherapeutics.com/science-overview/)\n\n[TRACER Platform](https://www.voyagertherapeutics.com/science-tracer/)\n\n[Non-Viral Delivery](https://www.voyagertherapeutics.com/science-non-viral/)\n\n[Publications & Presentations](https://www.voyagertherapeutics.com/science-publications/)\n\n[Partnerships](https://www.voyagertherapeutics.com/science-partnerships/)\n\nInvestors\n\n[Overview](/)\n\n[Press Releases](/press-releases)\n\n[Events & Presentations](/events-presentations)\n\n[Financials](/financial-information/sec-filings)\n\n[Stock Information](/stock-information/stock-quote)\n\n[Shareholder Services](/shareholder-services/investor-faqs)\n\nCareers\n\n[Overview](https://www.voyagertherapeutics.com/careers-overview/)\n\n[Job Openings](https://boards.greenhouse.io/voyagertherapeutics/)\n\n[Our Community](https://www.voyagertherapeutics.com/careers-culture/)\n\n[Mission & Values](https://www.voyagertherapeutics.com/about-core-values/)\n\n[Benefits](https://www.voyagertherapeutics.com/careers-benefits/)\n\n[Disclosures](https://www.voyagertherapeutics.com/careers-disclosures/)\n\nAbout\n\n[Overview](https://www.voyagertherapeutics.com/about-overview/)\n\n[Vision, Mission, & Strategy](https://www.voyagertherapeutics.com/about-vision-mission-strategy/)\n\n[Management Team](https://www.voyagertherapeutics.com/about-leadership/)\n\n[Board of Directors](https://www.voyagertherapeutics.com/about-leadership/#bod)\n\n[Scientific Advisory Board](https://www.voyagertherapeutics.com/about-leadership/#sab)\n\n[Core Values](https://www.voyagertherapeutics.com/about-core-values/)\n\nPipeline\n\n[Overview](https://www.voyagertherapeutics.com/pipeline-overview/)\n\n[• VY7523 for Alzheimer’s](https://www.voyagertherapeutics.com/pipeline-overview/?popup=vy7523)\n\n[• Alzheimer’s early research](https://www.voyagertherapeutics.com/pipeline-overview/?popup=alzheimers)\n\n[• SOD1 for ALS](https://www.voyagertherapeutics.com/pipeline-overview/?popup=sod1)\n\n[Patient Resources](https://www.voyagertherapeutics.com/patient-resources/)\n\n[Partnerships](https://www.voyagertherapeutics.com/science-partnerships/)\n\nScience\n\n[Overview](https://www.voyagertherapeutics.com/science-overview/)\n\n[TRACER Platform](https://www.voyagertherapeutics.com/science-tracer/)\n\n[Non-Viral Delivery](https://www.voyagertherapeutics.com/science-non-viral/)\n\n[Publications & Presentations](https://www.voyagertherapeutics.com/science-publications/)\n\n[Partnerships](https://www.voyagertherapeutics.com/science-partnerships/)\n\nInvestors\n\n[Overview](/)\n\n[Press Releases](/press-releases)\n\n[Events & Presentations](/events-presentations)\n\n[Financials](/financial-information/sec-filings)\n\n[Stock Information](/stock-information/stock-quote)\n\n[Shareholder Services](/shareholder-services/investor-faqs)\n\nCareers\n\n[Overview](https://www.voyagertherapeutics.com/careers-overview/)\n\n[Job Openings](https://boards.greenhouse.io/voyagertherapeutics/)\n\n[Our Community](https://www.voyagertherapeutics.com/careers-culture/)\n\n[Mission & Values](https://www.voyagertherapeutics.com/about-core-values/)\n\n[Benefits](https://www.voyagertherapeutics.com/careers-benefits/)\n\n[Disclosures](https://www.voyagertherapeutics.com/careers-disclosures/)\n\nSearch for:\n\n# Annual Reports\n\n  * [Overview](/ \"Main Investor Relations Page\")\n  * [Press Releases](/press-releases)\n  * [Events & Presentations](/events-presentations)\n  * [Financials](/financial-information/sec-filings)\n    * [SEC Filings](/financial-information/sec-filings)\n    * [Annual Reports](/financial-information/annual-reports)\n  * [Stock Information](/stock-information/stock-quote)\n    * [Stock Quote & Chart](/stock-information/stock-quote)\n  * [Corporate Governance]()\n    * [Leadership Team](https://www.voyagertherapeutics.com/about-leadership/#managementteam)\n    * [Board of Directors](https://www.voyagertherapeutics.com/about-leadership/#bod)\n    * [Scientific Advisors](https://www.voyagertherapeutics.com/about-leadership/#sab \"Code of Conduct\")\n    * [Committee Composition](/corporate-governance/committee-composition)\n    * [Documents & Charters](/corporate-governance/highlights)\n    * [Contact the Board](/corporate-governance/contact-the-board)\n  * [Shareholder Services](/shareholder-services/investor-faqs)\n    * [Investor FAQs](/shareholder-services/investor-faqs)\n    * [Analyst Coverage](/shareholder-services/analyst-coverage)\n    * [Contact Us](/shareholder-services/document-request)\n    * [Email Alerts](/shareholder-services/email-alerts)\n\n\n\n[2023 Annual Report](/static-files/617a03e9-b89c-46f2-a4f9-c8913849ee36 \"Voyager_2023_FullAnnualReport FINAL.pdf\") 3.6 MB\n\n[2022 Annual Report](/static-files/a59bdd26-4cba-4c45-99be-b5b8fe40d99d \"VYGR Annual Report 2022 Final Full.pdf\") 3 MB\n\n[2021 Annual Report](/static-files/a3624e9b-8e1a-4d7c-a45e-0dbffda9e983 \"Voyager_Annual_Report_2021.pdf\") 7.1 MB\n\n[2020 Annual Report](/static-files/32eb4132-1163-46d2-bde9-c5d1f9948fac \"VYGR - 2020 Annual Report - FINAL.pdf\") 3.2 MB\n\n[2019 Annual Report](/static-files/7b5f1610-89b2-4ec8-899d-565528b37560 \"Voyager 2019 Annual Report.PDF\") 3.6 MB\n\n[2018 Annual Report](/static-files/e0b37231-d6d6-400f-b7fa-7c01b42166fd \"VYGR_FINAL annual report April 2019.PDF\") 4.8 MB\n\n[2017 Annual Report](/static-files/5f91d500-4d1e-455b-82a1-f2c5aec00a33 \"Voyager Theraputics 2017 Final annual report.pdf\") 4.3 MB\n\n[2016 Annual Report](/static-files/8edd875f-1dd0-4760-b5f6-2812df188d1b \"Voyager Final annual report for 2016.pdf\") 4.4 MB\n\n[2015 Annual Report](/static-files/16cb7b1e-5dd7-453b-83f4-d106b3f0ae2d \"VYGR_2015 Annual Report.pdf\") 2.4 MB\n"
        }
      ]
    }
  ]
}